(Q42223359)

18 October 2017

ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type (English)

1 reference

18 October 2017

K Matsuura

1

1 reference

18 October 2017

Y Tanaka

2

1 reference

18 October 2017

T Watanabe

3

1 reference

18 October 2017

K Fujiwara

4

1 reference

18 October 2017

E Orito

5

1 reference

18 October 2017

M Kurosaki

6

1 reference

18 October 2017

N Izumi

7

1 reference

18 October 2017

N Sakamoto

8

1 reference

18 October 2017

N Enomoto

9

1 reference

18 October 2017

H Yatsuhashi

10

1 reference

18 October 2017

A Kusakabe

11

1 reference

18 October 2017

N Shinkai

12

1 reference

18 October 2017

S Nojiri

13

1 reference

18 October 2017

T Joh

14

1 reference

18 October 2017

M Mizokami

15

1 reference

18 October 2017

3 September 2013

1 reference

Journal of Viral Hepatitis

18 October 2017

1 reference

18 October 2017

21

1 reference

18 October 2017

466-474

1 reference

18 October 2017

7

1 reference

The global burden of hepatitis C

18 October 2017

1 reference

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

21 January 2018

1 reference

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

21 January 2018

1 reference

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C pharmacogenetics: state of the art in 2010.

21 January 2018

1 reference

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

21 January 2018

1 reference

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

21 January 2018

1 reference

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin

21 January 2018

1 reference

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

21 January 2018

1 reference

Factors contributing to ribavirin-induced anemia

21 January 2018

1 reference

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

21 January 2018

1 reference

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

21 January 2018

1 reference

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population

21 January 2018

1 reference

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

21 January 2018

1 reference

Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6.

21 January 2018

1 reference

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12171

1 reference

18 October 2017

1 reference